Security key
24823R105
Denali Therapeutics Inc. - COMMON STOCK (DNLI)
CUSIP: 24823R105
Q3 2021 13F Holders as of 30 Sep 2021
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 82,102,816
- Total 13F value
- $4,142,844,228
- Share change
- +3,804,883
- Put/Call ratio
- 42%
- SEC-reported price per share
- $50.45
- Number of holders
- 205
- Value change
- +$169,589,833
- Number of buys
- 108
- Number of sells
- 93
- Shares outstanding
- 157,762,815
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2021
Institutions
205
Top holders
10
DNLI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2021
Previous quarter: Q2 2021
Denali Therapeutics Inc. SEC filings
Denali Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 24823R105
Recent filing periods:
Ownership snapshot
Top reported holders of DNLI - Denali Therapeutics Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
BAILLIE GIFFORD & CO
Comparable rows
15/15
Latest evidence
30 Jun 2021
13F
Lead comparable stake: 9.6%
Showing 1-6 of 15 holder rows.
Quick read
BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 9.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership
Top 5
BAILLIE GIFFORD & CO
9.6%
Crestline Management, L.P.
5.2%
VANGUARD GROUP INC
4.8%
BlackRock Finance, Inc.
4.5%
PRICE T ROWE ASSOCIATES INC /MD/
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO |
13F
Company
|
9.6%
|
$1,188,179,000
15,147,613 shares
|
— | 30 Jun 2021 |
| Crestline Management, L.P. |
13F
Company
|
5.2%
|
$638,147,000
8,135,481 shares
|
— | 30 Jun 2021 |
| VANGUARD GROUP INC |
13F
Company
|
4.8%
|
$599,605,000
7,644,130 shares
|
— | 30 Jun 2021 |
| BlackRock Finance, Inc. |
13F
Company
|
4.5%
|
$551,906,000
7,036,041 shares
|
— | 30 Jun 2021 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
3.1%
|
$384,627,000
4,903,452 shares
|
— | 30 Jun 2021 |
| Temasek Holdings (Private) Ltd |
13F
Company
|
2.8%
|
$345,956,000
4,410,457 shares
|
— | 30 Jun 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2021
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
205
Shares
82,102,816
Rows available
205
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2021 vs Q2 2021 Across Filers
Q2 2021 holders
204
Q3 2021 holders
205
Holder diff
1
| Investor | Q2 2021 Shares | Q3 2021 Shares | Share Diff | Share Chg % | Q2 2021 value | Q3 2021 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend